Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma

Cancer Journal from Scientific American

Volumn 2, Issue 2, 1996, Pages 91-98

  Royal, Richard E ^a   Steinberg, Seth M ^a   Krouse, Robert S ^a   Heywood, Glenroy ^a   White, Donald E ^a   Hwu, Patrick ^a   Marincola, Franco M ^a   Parkinson, David R ^a   Schwartzentruber, Douglas J ^a   Topalian, Suzanne L ^a   Yang, James C ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Interteukin 2; Lymphocytosis; Melanoma; Neoplasm metastasis; Prognosis; Renal cell carcinoma; Thrombocytopenia

Indexed keywords

INTERLEUKIN 2; RECOMBINANT PROTEIN;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOTHERAPY; KIDNEY TUMOR; LYMPHOCYTOSIS; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTOSIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0002018122     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lotze MT. Biologic therapy with interleukin-2: preclinical studies. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: J.B. Lippincott, 1995:207-223.
2. Rosenberg SA, Grimm EA, McGrogan M et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984;223:1412-1415.
3. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwartz SL. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;75:67-75.
4. Fisher RI, Coltman CA, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells, a phase II clinical trial. Ann Intern Med 1988;108:518-523.
5. Weiss GR, Margolin KA, Aronson FR et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-281.
6. Atkins MB, Sparano J, Fisher RI et al. Randomized phase II trial of high-dose interleukin-2 alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-670.
7. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
8. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-1874.
9. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485.
10. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
11. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-632.
12. Parkinson DR, Abrams JS, Wiernik PH et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990;10:1650-1656.
13. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. JAMA 1986;256:3117-3124.
14. Mier JW, Aronson FR, Numerof RP, Vachino G, Atkins MB. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res 1988;7:459-476.
15. Schwartzentruber DJ. Biologic therapy with interleukin-2: clinical applications, principles of administration and management of side effects. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: J.B. Lippincott, 1995:235-249.
16. White RL, Schwartzentruber DJ, Guleria A et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994;74:3212-3222.
17. Guleria AS, Yang JC, Topalian SL et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994;12:2714-2722.
18. MacFarlane MP, Yang JC, Guleria AS et al. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer 1995;75:1030-1037.
19. Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-1576.
20. Yang JC, Topalian SL, Schwartzentruber DJ et al. The use of polyethylene-glycol-modified interleukin-2 (PEG-IL2) in the treatment of patients with metastatic renal cell carcinoma and melanoma: a phase I study and randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL2. Cancer 1995;76:687-694.
21. Dummer R, Gore ME, Hancock BW et al. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Cancer 1995;15;1038-1044.
22. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313.
23. Lissoni P, Barni S, Ardizzoia A et al. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 1994;51:59-62.
24. Palmer PA, Vinke J, Philip T et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-480.
25. Jones M, Phillip T, Palmer P et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8:275-288.
26. Malkovska Z, Hank J, Sondel PM, Sosman JA. Low-dose IL-2 in cancer therapy. In: Atkins MB, Mier JW, eds. Therapeutic Applications of Interleukin-2. New York: Marcel Dekker, 1993:143-161.
27. Marincola FM, Venzon D, White D et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 1992;52:6561-6566.
28. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alpha-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995;13:1110-1122.
29. Paciucci PA, Holland JF, Glidewell O, Odchimar R. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. J Clin Oncol 1989;7:869-878.
30. West WH, Tauer KW, Yanelli JR et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
31. Paciucci PA. Immunotherapy of metastatic melanoma with interleukin-2. Mt Sinai J Med 1992;59:238-243.
32. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies. Lancet 1990;335:1509-1512.
33. Ho RC. Medical management of stage IV malignant melanoma. Cancer 1995;15:735-741.
34. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989;49:7086-7092.
35. Scheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M, Hunstein W. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-α) and interleukin-2 (IL-2). Melanoma Res 1994;4:191-194.
36. Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res 1990;50:2371-2374.
37. Tartour E, Dorval T, Mosseri V et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994;69:911-913.
38. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;15:3317-3322.